marked.bio

EGFR-HER3 bispecific ADC · ADC

JS212

3 active trials across 8 of our biomarkers, targeting EGFR x HER3. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
EGFR exon 19 deletion / L858R 3 3 Phase 2
ALK fusion 1 1 Phase 2
BRAF V600E 1 1 Phase 2
HER2 (ERBB2) activating mutation 1 1 Phase 2
KRAS G12C 1 1 Phase 2
NTRK1/2/3 fusion 1 1 Phase 2
RET fusion or mutation 1 1 Phase 2
ROS1 fusion 1 1 Phase 2

Trials

3 of 3 trials shown

  1. JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study

    Recruiting Phase 2 Shanghai Junshi Bioscience Started 2026Primary completion 2028-04 NCT07518160

    JS212

    Exon 19 deletion or L858R mutation,Either alone or in combination with other EGFR mutations, Including tho…

    EGFR exon 19 deletion / L858RLocally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

  2. Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy

    Recruiting Phase 2 Shanghai Junshi Bioscience Started 2025Primary completion 2026-09 NCT06868836

    JS207pemetrexedcarboplatincisplatinJS212

    … exon G719X mutation, 19 exon deletion mutation, 20 exon S768I or T790M mutation, 21 exon L858R or L861Q mutation), ALK fusion, ROS1 fusion, BRAF V600E mutation, NTRK fusion, MET14 exon…

    EGFR exon 19 deletion / L858RKRAS G12CBRAF V600EHER2 (ERBB2) activating mutationALK fusionROS1 fusionRET fusion or mutationNTRK1/2/3 fusionNon-squamous Non-small Cell Lung Cancer

  3. JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC

    Not yet recruiting No phase Huan Zhou Started 2026Primary completion 2026-11 NCT07714304

    JS212JS111 capsules (AP-L1898)

    Confirmed EGFR-sensitizing mutation, defined as an exon 19 deletion or L858R mutation, either occurring alone or together with other EGFR mutations, includin…

    EGFR exon 19 deletion / L858RNSCLC Harboring EGFR Mutations